Using similar science, page-21

kadaicher1, your point to champion the occurrence of MICROhemorrhages in 2011 by a failed drug has no place in today's scientific world. Those early pioneering trials resulted in knowledge which was shared with scientists globally who now are proceeding toward assured safety and probable efficacy as AD research proceeds. Following many failures of those targeting beta amyloid, there is much work ahead to prove the value of the amyloid beta hypothesis and therapeutics such as aducanumab and PBT2.

I believe that your side journey reference to an early therapeutic discovered by a company that closed its doors many years ago cannot be compared to a going concern like Biogen and others who are vigorously monitoring and managing side effects in thorough dosage testing in extensive and well-powered Phase III clinical trials. You may recall that Prana's once prime candidate clioquinol had its own safety problems and that history remains unresolved as Prana has yet to provide sufficient proof to the FDA of safety of PBT2. Oh yes, they are working on it.